title: Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis.
authors.affiliation: Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland. kari.eklund@HUS.fi
authors.forename: Kari K
authors.initials: KK
authors.lastname: Eklund
authors.forename: Ken
authors.initials: K
authors.lastname: Lindstedt
authors.forename: Charlotta
authors.initials: C
authors.lastname: Sandler
authors.forename: Petri T
authors.initials: PT
authors.lastname: Kovanen
authors.forename: Leena
authors.initials: L
authors.lastname: Laasonen
authors.forename: Annika
authors.initials: A
authors.lastname: Juurikivi
authors.forename: Henrik
authors.initials: H
authors.lastname: Wolff
authors.forename: Marko
authors.initials: M
authors.lastname: Mykkänen
authors.forename: Heikki
authors.initials: H
authors.lastname: Joensuu
mesh_terms: D000328:Adult; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D010147:Pain Measurement; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate